Rad1901, an orally available SERD also retains efficacy in the presence of ESR1 mutations, and was recently FDA-approved for patients with ESR1 mutated advanced ER+ breast cancer based on the positive results of the phase III EMERALD trial [35]. The gene discussed is ESR1; the disease is breast carcinoma.